Skip to main content

Table 2 MD Anderson Cancer Center Residual Cancer Burden Index

From: Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Residual Cancer Score N = 49*
Class I 2 (4.1%)
Class II 20 (40.8%)
Class III 27 (55.1%)
  1. *The MD Anderson Cancer Center Residual Cancer Burden Index cannot be calculated in one patient with tumor cells present only in the lymphovascular space